Omeros

NASDAQ: OMER ↗ $10.28 USD ~$350M MCAP

#Complement-Mediated Diseases #Transplant-Associated Thrombotic Microangiopathy (TA-TMA)#Hematopoietic Stem Cell Transplantation #Central Nervous System Disorders #Immune-Related Disorders

Omeros Corporation is a Seattle-based biopharmaceutical company developing small-molecule and biologic therapies for complement-mediated diseases, immune-related disorders, and central nervous system conditions. Its first commercial product, Yartemlea (narsoplimab), is the first FDA-approved treatment for transplant-associated thrombotic microangiopathy (TA-TMA) in hematopoietic stem cell transplantation.

Company Info

Sector: Biotechnology / Therapeutics

Headquarters: Seattle, Washington, USA

Founded: 1994

Website: www.omeros.com/

Upcoming Milestones & Key Dates

January 2026

Launch

U.S. commercial launch of Yartemlea (narsoplimab) for TA-TMA

Late 2026

Regulatory

Targeted BLA submission by partner Novo Nordisk for zaltenibart (OMS906) in PNH

Clinical Development Pipeline

Yartemlea (narsoplimab)

Target: MASP-2 (Mannan-Binding Lectin-Associated Serine Protease-2)

Transplant-Associated Thrombotic Microangiopathy (TA-TMA)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Zaltenibart (OMS906)

Target: MASP-3 inhibitor

Paroxysmal Nocturnal Hemoglobinuria (PNH) (licensed to Novo Nordisk)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

OMS527

Target: Phosphodiesterase 7 (PDE7) inhibitor

Cocaine Use Disorder (CUD)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Gregory A. Demopulos, M.D.

Chairman, President and Chief Executive Officer

Michael A. Jacobs

Vice Chairman and Lead Independent Director

David J. Mai

Vice President, Finance and Chief Accounting Officer

Careers & Job Openings

See all open roles

Multiple Departments

See careers page

Apply Now →